Mynvax: Publications

Who We Are
Our Journey Leadership Team Scientific Advisory Board
Technology
Vaccine Design Workflow Publications Intellectual Property
Programs
Influenza Covid 19
Partners
Careers
Working at Mynvax Current Opportunities
News

Publications

12) Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice. Pharmaceutics (2023)
doi: 10.3390/pharmaceutics15122759 ; PMID: 38140101

11) Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants. NPJ Vaccines (2023)
doi: 10.1038/s41541-023-00755-2 ; PMID: 37880298

10) Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity. J Virol. (2023)
doi: 10.1128/jvi.00922-23 ; PMID: 37861334

9) Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses (2023)
doi: 10.3390/v15020346 ; PMID: 36851560

8) Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2. J Phys Chem B (2023)
doi: 10.1021/acs.jpcb.2c07262. ; PMID: 36790910

7) Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens. Front Immunol (2022)
doi: 10.3389/fimmu.2022.890622 ; PMID: 35720346

6) Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice. Viruses (2022)
doi: 10.3390/v14040800 ; PMID: 35458530

5) A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. Front Immunol. (2021)
doi: 10.3389/fimmu.2021.765211 ; PMID: 34956193

4) Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions. Viruses (2021)
doi: 10.3390/v13091710 ; PMID: 34578291

3) Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infect Dis. (2021)
doi: 10.1021/acsinfecdis.1c00276 ; PMID: 34260218

2) Conformational flexibility and structural variability of SARS-CoV2 S protein. Structure (2021)
doi: doi: 10.1016/j.str.2021.04.006 ; PMID: 33932324

1) Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem. (2021)
doi: doi: 10.1074/jbc.RA120.016284 ; PMID: 33154165

MYNVAX PRIVATE LIMITED
Corporate Identification Number (CIN): U73200KA2017PTC102838
Registered Office Address: Brigade MLR Center, 3rd Floor, No.50, Vani Vilas Road, Basavanagudi, Bengaluru, 560004
📍 View on Google Maps

Contact us +91 80 4991 1864/ 4991 1866

Publications

12) Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice. Pharmaceutics (2023) doi: 10.3390/pharmaceutics15122759 ; PMID: 38140101

doi: 10.3390/pharmaceutics15122759 ; PMID: 38140101

11) Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants. NPJ Vaccines (2023) doi: 10.1038/s41541-023-00755-2 ; PMID: 37880298

doi: 10.1038/s41541-023-00755-2 ; PMID: 37880298

10) Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity. J Virol. (2023) doi: 10.1128/jvi.00922-23 ; PMID: 37861334

doi: 10.1128/jvi.00922-23 ; PMID: 37861334

9) Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses (2023) doi: 10.3390/v15020346 ; PMID: 36851560

doi: 10.3390/v15020346 ; PMID: 36851560

8) Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2. J Phys Chem B (2023) doi: 10.1021/acs.jpcb.2c07262. ; PMID: 36790910

doi: 10.1021/acs.jpcb.2c07262. ; PMID: 36790910

7) Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens. Front Immunol (2022) doi: 10.3389/fimmu.2022.890622 ; PMID: 35720346

doi: 10.3389/fimmu.2022.890622 ; PMID: 35720346

6) Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice. Viruses (2022) doi: 10.3390/v14040800 ; PMID: 35458530

doi: 10.3390/v14040800 ; PMID: 35458530

5) A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. Front Immunol. (2021) doi: 10.3389/fimmu.2021.765211 ; PMID: 34956193

doi: 10.3389/fimmu.2021.765211 ; PMID: 34956193

4) Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions. Viruses (2021) doi: 10.3390/v13091710 ; PMID: 34578291

doi: 10.3390/v13091710 ; PMID: 34578291

3) Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infect Dis. (2021) doi: 10.1021/acsinfecdis.1c00276 ; PMID: 34260218

doi: 10.1021/acsinfecdis.1c00276 ; PMID: 34260218

2) Conformational flexibility and structural variability of SARS-CoV2 S protein. Structure (2021) doi: doi: 10.1016/j.str.2021.04.006 ; PMID: 33932324

doi: doi: 10.1016/j.str.2021.04.006 ; PMID: 33932324

1) Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem. (2021) doi: doi: 10.1074/jbc.RA120.016284 ; PMID: 33154165

doi: doi: 10.1074/jbc.RA120.016284 ; PMID: 33154165